Life challenges make this population very difficult to treat, but interventions that take their issues into account may ...
GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
In a milestone decision, the Peruvian Congress has passed legislation that extends temporary health insurance coverage to ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Llama Nanobodies: A Breakthrough in Building HIV Immunity July 17, 2024 — Biology researchers have developed a new antibody therapy that can neutralize a wide variety of HIV-1 strains.
Kidney transplant between donors and recipients with HIV is successful, research shows, which may help addresses the organ ...
Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback